Hunan Nucien Pharmaceutical Co Ltd
Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascula… Read more
Market Cap & Net Worth: Hunan Nucien Pharmaceutical Co Ltd (688189)
Hunan Nucien Pharmaceutical Co Ltd (SHG:688189) has a market capitalization of $296.94 Million (CN¥2.18 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #16188 globally and #4299 in its home market, demonstrating a 0.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Nucien Pharmaceutical Co Ltd's stock price CN¥7.94 by its total outstanding shares 274400000 (274.40 Million).
Hunan Nucien Pharmaceutical Co Ltd Market Cap History: 2020 to 2026
Hunan Nucien Pharmaceutical Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $925.51 Million to $296.94 Million (-21.22% CAGR).
Hunan Nucien Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Nucien Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.93x
Hunan Nucien Pharmaceutical Co Ltd's market cap is 0.93 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $925.51 Million | $1.03 Billion | $127.97 Million | 0.90x | 7.23x |
| 2021 | $672.02 Million | $743.66 Million | -$161.88 Million | 0.90x | N/A |
| 2022 | $461.07 Million | $698.83 Million | -$78.83 Million | 0.66x | N/A |
| 2023 | $352.67 Million | $720.06 Million | -$10.87 Million | 0.49x | N/A |
| 2024 | $244.58 Million | $263.28 Million | -$356.90 Million | 0.93x | N/A |
Competitor Companies of 688189 by Market Capitalization
Companies near Hunan Nucien Pharmaceutical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Hunan Nucien Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Hunan Nucien Pharmaceutical Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Hunan Nucien Pharmaceutical Co Ltd's market cap moved from $925.51 Million to $ 296.94 Million, with a yearly change of -21.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥296.94 Million | -0.38% |
| 2025 | CN¥298.06 Million | +21.87% |
| 2024 | CN¥244.58 Million | -30.65% |
| 2023 | CN¥352.67 Million | -23.51% |
| 2022 | CN¥461.07 Million | -31.39% |
| 2021 | CN¥672.02 Million | -27.39% |
| 2020 | CN¥925.51 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hunan Nucien Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $296.94 Million USD |
| MoneyControl | $296.94 Million USD |
| MarketWatch | $296.94 Million USD |
| marketcap.company | $296.94 Million USD |
| Reuters | $296.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.